Nichiban Co., Ltd. (JP:4218)
:4218
Want to see JP:4218 full AI Analyst Report?
Top Page
Nichiban Co., Ltd.
(4218)
Select Model
Select Model
Rating:65Neutral
Price Target:
¥2,039.00
▲(2.05% Upside)
Action:Downgraded
Date:05/15/26
The score is primarily supported by a strong, low-leverage balance sheet, but tempered by weakening earnings and inconsistent cash-flow generation. Technical indicators add a mild drag due to negative momentum and trading below longer-term averages, while valuation is reasonable with a modest dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage and rising equity provide durable financial flexibility: reduces refinancing and solvency risk, supports investment or cushioning in downturns, and preserves capacity for strategic capex or M&A without jeopardizing core operations over the next several months.
Negative Factors
Weakened profitability and margins
Declining net income and recent operating profit drops point to margin compression or rising costs. Sustained weaker profitability reduces internal investment capacity, limits reinvestment and dividend growth, and risks undermining long-term competitiveness if structural cost pressures persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and rising equity provide durable financial flexibility: reduces refinancing and solvency risk, supports investment or cushioning in downturns, and preserves capacity for strategic capex or M&A without jeopardizing core operations over the next several months.
Read all positive factors
Nichiban Co., Ltd. (4218) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥38.73B
Dividend Yield1.77%
Average Volume (3M)13.87K
Price to Earnings (P/E)24.7
Beta (1Y)0.50
Revenue Growth2.05%
EPS Growth-15.62%
CountryJP
Employees1,270
SectorIndustrials
Sector Strength72
IndustryBusiness Equipment & Supplies
Share Statistics
EPS (TTM)99.18
Shares Outstanding20,738,007
10 Day Avg. Volume15,410
30 Day Avg. Volume13,873
Financial Highlights & Ratios
PEG Ratio-1.48
Price to Book (P/B)0.86
Price to Sales (P/S)0.76
P/FCF Ratio77.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)88.4
Revenue Forecast (FY)¥51.13B
Nichiban Co., Ltd. Business Overview & Revenue Model
Company Description
Nichiban Co., Ltd. manufactures and sells medical products and tapes in Asia and Europe. It offers medical products, including surgical tapes, dressing tapes, first-aid bandages, hemostatic bandages, and others. The company also provides OTC produ...
How the Company Makes Money
Nichiban makes money primarily by manufacturing and selling adhesive-based products. Key revenue streams include: (1) Industrial and packaging-related adhesive tapes and materials sold to corporate customers for logistics, manufacturing, construct...
Nichiban Co., Ltd. Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
84
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.86B | 50.47B | 49.46B | 46.86B | 45.56B | 43.13B |
| Gross Profit | 15.05B | 15.03B | 14.90B | 13.87B | 12.97B | 13.50B |
| EBITDA | 5.80B | 5.11B | 5.73B | 4.87B | 4.37B | 5.00B |
| Net Income | 2.02B | 1.65B | 1.96B | 1.83B | 2.37B | 1.81B |
Balance Sheet | ||||||
| Total Assets | 67.40B | 67.31B | 68.58B | 69.01B | 69.92B | 65.12B |
| Cash, Cash Equivalents and Short-Term Investments | 15.76B | 14.13B | 14.66B | 13.40B | 15.11B | 14.20B |
| Total Debt | 2.18B | 2.17B | 2.12B | 2.13B | 2.14B | 2.15B |
| Total Liabilities | 24.64B | 22.98B | 25.39B | 27.30B | 29.31B | 26.16B |
| Stockholders Equity | 42.76B | 44.33B | 43.19B | 41.70B | 40.60B | 38.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 495.00M | 2.35B | -439.00M | 338.00M | 1.52B |
| Operating Cash Flow | 0.00 | 2.54B | 3.69B | 3.19B | 2.92B | 4.06B |
| Investing Cash Flow | 0.00 | -2.24B | -1.70B | -3.69B | -1.15B | -2.90B |
| Financing Cash Flow | 0.00 | -1.11B | -763.00M | -1.23B | -867.00M | -691.00M |
Nichiban Co., Ltd. Technical Analysis
Negative
1998.00
Price Trends
1868.21
Negative
1898.25
Negative
1913.57
Negative
Market Momentum
-0.23
Negative
50.60
Neutral
44.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4218, the sentiment is Negative. The current price of 1998 is above the 20-day moving average (MA) of 1850.10, above the 50-day MA of 1868.21, and above the 200-day MA of 1913.57, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 50.60 is Neutral, neither overbought nor oversold. The STOCH value of 44.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4218.
Nichiban Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥134.68B | 12.67 | ― | 2.09% | 0.66% | -30.89% | |
71 Outperform | ¥173.35B | 15.82 | ― | 2.56% | 1.83% | -7.02% | |
65 Neutral | ¥38.73B | 24.66 | ― | 1.77% | 2.05% | -15.62% | |
64 Neutral | ¥341.69B | 9.14 | 8.83% | 2.33% | 7.82% | 13.39% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
61 Neutral | ¥22.58B | 17.75 | ― | 1.69% | -2.48% | 161.85% | |
47 Neutral | ¥3.96B | 62.78 | ― | 2.03% | -1.04% | -83.70% |
* Industrials Sector Average
JP:4218
Nichiban Co., Ltd.
1,866.00
-43.50
-2.28%
JP:7984
Kokuyo Co
802.40
67.95
9.25%
JP:7846
Pilot Corporation
4,922.00
1,084.98
28.28%
JP:7962
King Jim Co., Ltd.
793.00
-53.10
-6.28%
JP:7975
LIHIT LAB., INC.
1,152.00
33.16
2.96%
JP:7976
Mitsubishi Pencil Company, Limited
2,623.00
555.42
26.86%
Nichiban Co., Ltd. Corporate Events
Nichiban Raises Year-End Dividend and Signals Ongoing Commitment to Shareholder Returns
May 14, 2026
Nichiban Co., Ltd. has approved a year-end dividend of 40 yen per share for the fiscal year ended March 31, 2026, with a total payout of 807 million yen, up from 35 yen and 712 million yen, respectively, in the previous year. The company plans to ...
Nichiban Affirms Independence Despite 33.52% Stake Held by Taiho Pharmaceutical
May 14, 2026
Nichiban Co., Ltd. disclosed that Taiho Pharmaceutical Co., Ltd. is an other associated company holding 33.52% of its voting rights, yet stresses that there are no approval requirements or other constraints from Taiho on its business activities. N...
Nichiban Posts Profit Decline but Lifts Dividend and Projects Strong Earnings Rebound
May 14, 2026
Nichiban Co., Ltd. reported a 2.0% rise in net sales to ¥50.47 billion for the fiscal year ended March 31, 2026, but operating profit fell 12.2% and profit attributable to owners of parent declined 15.7%, compressing margins and reducing basi...
Nichiban Completes Treasury Share Buyback to Bolster Capital Flexibility
Mar 11, 2026
Nichiban Co., Ltd. has completed a share repurchase program authorized by its board on March 10, 2026, acquiring 176,500 common shares for a total of 342,586,500 yen via the Tokyo Stock Exchange’s off-auction own share repurchase trading sys...
Nichiban to Launch ¥450 Million Share Buyback via ToSTNeT-3
Mar 10, 2026
Nichiban Co., Ltd. has decided to repurchase up to 200,000 of its common shares, equivalent to about 0.98% of its outstanding stock excluding treasury shares, through the Tokyo Stock Exchange’s off-auction own share repurchase system (ToSTNe...
Nichiban Launches Share Buyback of Up to 200,000 Shares
Mar 10, 2026
Nichiban Co., Ltd. has resolved to acquire up to 200,000 of its own common shares, representing about 0.98% of its outstanding stock, for a maximum of 450 million yen. The buyback will take place between March 11 and March 31, 2026, via off-auctio...
Nichiban Details Financial Results and Governance of Key Pharmaceutical Parent Company
Mar 10, 2026
Nichiban Co., Ltd. has disclosed the fiscal 2025 financial results of its parent-related company, Taiho Pharmaceutical Co., Ltd., underscoring Taiho’s status as a key associated company with a 33.22% voting stake in Nichiban and active produ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.